Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 16 systematic review(s)/meta-analysis(es). ^[1-16]
• T-DM1 demonstrated superior overall survival (OS) and progression-free survival (PFS) in patients with HER2+ metastatic breast cancer, with improvements in OS (HR (hazard ratio): 0.75) and PFS (HR: 0.67) compared to regimens such as Capecitabine, Lapatinib-Capecitabine, and Trastuzumab-Capecitabine.
• In patients with brain metastases, T-DM1 (trastuzumab emtansine) and Trastuzumab-deruxtecan (T-DXd) exhibited the highest objective response rates, indicating their efficacy in this specific population.
• Canagliflozin showed benefits for patients with severe chronic kidney disease (eGFR (estimated glomerular filtration rate) < 45 mL/min/1.73 m²), with consistent outcomes across various levels of baseline eGFR, enhancing its applicability in high-risk populations.
• The safety profile of T-DM1 revealed a higher incidence of elevated liver transaminases and thrombocytopenia, while it had a lower rate of gastrointestinal side effects compared to other treatments.
• The safety profile of T-DM1 varied by population, with different adverse event rates observed, particularly in Asian populations compared to the general population. Additionally, T-DM1 and other systemic HER2-targeted therapies showed acceptable safety profiles in patients with brain metastases.
• In combination with radiation therapy, T-DM1 had a high incidence of grade 3+ radionecrosis but low rates of grade 3+ radiation-related pneumonitis and skin toxicity, suggesting that while generally safe, caution is needed when irradiating intracranial sites.
• Safety profiles for T-DM1 varied by population and treatment line, with different adverse event rates noted in Asian populations compared to the general population, highlighting the need for tailored monitoring and management strategies based on demographic factors.